Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionCombination of fluticasone propionate and salmeterol xinafoate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase I
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today